Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures
Completed
Eisai Inc.
Phase 3
2006-02-13
To evaluate the effect of rufinamide on total partial seizure frequency in adolescent and
adult participants (12 to 80 years, inclusive) with refractory partial onset seizures
maintained on a maximum of 3 stable antiepileptic drugs (AEDs).
Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
Terminated
Eisai Inc.
Phase 3
2007-03-15
This was an open-label extension study in adolescent and adult (between 12 and 80 years old)
participants who had completed their participation in Study E2080-A001-301. The main
objective of this study was to evaluate the safety and efficacy of long-term administration
of rufinamide for the control of epileptic seizures in participants who had refractory
partial seizures despite treatment with a maximum of three approved antiepileptic drugs
(AEDs).
Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)
Completed
INC Research
Phase 2
2008-03-01
A Multi-Centered Randomized, Double-Blind, Placebo-Controlled, Phase 2, Exploratory Study to
Evaluate the Effect of Rufinamide on Anxiety in Patients with Moderate to Severe Generalized
Anxiety Disorder.
Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)
Completed
Syneos Health
Phase 2
2008-03-01
A Multi-Centered Randomized, Double-Blind, Placebo-Controlled, Phase 2, Exploratory Study to
Evaluate the Effect of Rufinamide on Anxiety in Patients with Moderate to Severe Generalized
Anxiety Disorder.
Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)
Completed
Biotie Therapies Inc.
Phase 2
2008-03-01
A Multi-Centered Randomized, Double-Blind, Placebo-Controlled, Phase 2, Exploratory Study to
Evaluate the Effect of Rufinamide on Anxiety in Patients with Moderate to Severe Generalized
Anxiety Disorder.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
